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312 Pre-emptive transjugular intrahepatic porto-systemic shunt
(TIPSS) for portal hypertension from cystic ﬁbrosis liver disease:
1 year evaluation
E. Robberecht1, L. Defreyne1. 1UZ Ghent, CF Centre, Ghent, Belgium
Background: Though oesophageal variceal bleeding is regarded as the main
complication of portal hypertension (PH) from cystic ﬁbrosis (CF) liver disease
increasing splenomegaly causes earlier concern when provoking abdominal discom-
fort, appetite loss by gastric compression and hypersplenisme. Treatment lacking,
the potential of preventive TIPSS, before variceal bleeding, was investigated.
Patients: In 5 children (M4.9 y; range 4−7.5 y) annual ultrasound, ﬁbroscan and
systematic clinical examination detected liver abnormalities. When they persisted
TIPSS was installed after 1.3−4.5 y (M2.5 y) to arrest progression of PH.
Results: In the ﬁrst year TIPSS did not change PH complications i.e. existing ab-
normalities remained while non present ones dit not develop. It slowed progression
of PH consequences on spleen size and function but did not reverse existing ones.
No oesophageal bleeding, ascites or side effects occured. Subjective complaints
and quality of life improved. In all patients TIPSS placement caused a persistent
deterioration of serum albumin and INR, remaining unaltered since.
Patient
1 2 3 4 5
Clinical splenic enlargement* +++/+++ +++/+++ +/+ 0/0 0/0
Platelets (103/mL) 55/63 62/38 264/269 242/197 196/233
INR * 1.34/1.61 1.34/1.80 1.03/1.1 1.00/1.20 1.01/1.13
Albumin (g/dL)* 3.94/3.66 3.31/3.7 4.46/4.22 4.33/4.1 4.21/3.7
*At TIPSS placement/1 y later.
Conclusion: In the ﬁrst year after placement TIPSS arrested progression of PH
and its consequences on spleen and oesophageal varices. If conﬁrmed pre-emptive
TIPSS can be promising if timed early, at the ﬁrst signs of progressive LF, before
splenic enlargement and oesophageal varices are established.
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CF related liver disease (CFLD) is a signiﬁcant cause of morbidity and mortality.
Portal hypertension increases the risk of death and LTx can be the only treament if
lung function is only moderately impaired.
Aim: Retrospective review of cases considered for LTx over the last 9 years.
Methods: From 1990 to 2009 380 pts received 429 LTx, out of these 7 with CF
(1.63%) since 2001. Before LTx all CF pts presented liver cirrhosis, portal hypertension
and oesophageal varices bleeds. Pt 5 underwent splenectomy and had chronic HCV
infection. Pt 4 was qualiﬁed as an urgent recipient due to acute liver failure.
Results: 7 CF pts received 8 allografts, 2 from related (pts 1, 3) and 6 from cadaveric
donors.
Patients’ data pre and post LTx
Pt Gender CFTR
mutations
Waiting
time (mo)
age at LTx
(yr)
FEV1 pre/post
(%pred)
BMI
pre/post
Survival
time (yr)
1 M dF508/dF508 6 8.3 91.46/84.68 14.6/15.7 8.7
2 M dF508/G542X 12 7.6 103.98/89.17 14.6/17.4 7.5
3 F dF508/dF508 6 10 81.71/− 16.0/− 0.2
4 F dF508/R553X 32 13.8 62.08/54.38 17.1/16.6 5.5
5 M dF508/dF508 1 18 102.95/79.55 18.8/19.7 3.8
6 M dF508/R437P 2 7.3 130.60/112.20 14.0/13.8 0.3
7 M dF508/dF508 6 12.2 80.08/− 17.1/15.9 0.2
mean±SD
9.29±10.63
mean±SD
11±3.9
mean±SD
3.7±3.6
The following major complications occured: thrombosis of hepatic artery (pts 3, 4),
acute rejection (pts 3, 5), renal insufﬁciency (pt 5), biliary complications (pts 1, 2, 7),
respiratory infections (pts 1, 3, 4), diabetes (pts 1, 4). Pt 3 who underwent reLTx for
primary allograft rejection died of systemic multiorgan failure.
Conclusions: Respiratory status has remained unchanged except pt 4. There was no
or slight improvement in nutritional status. LTx is acceptable treatment for pts with
CFLD and mild to moderate pulmonary disease.
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Aim: To evaluate long term outcome of LT in adults (A) and children (C) with CFLD.
Methods: Retrospective review of adults (21, 16M/5F) and children (19, 11M/8F)
with CFLD who underwent LT in Birmingham between 1987–2009. Data included
demographics, indications, nutritional data [BMI (A), height/weight z-scores (C)], lung
function [%FEV1/FVC (A), FEV1/FVC z-scores (C)], renal function (calculated GFR)
and post LT complications.
Results: 1and 5 yr actuarial survival rates were 85% and 64% for (A) and 90% and
85% for (C) respectively, comparable to survival rates for other indications.
at LT 6 mths 12 mths 24 mths 60 mths
median %FEV1 49.2 49.5 48.8 41.3 37.6
FEV1 z-score −1.51 −1.07 −1.00 −1.22
BMI 19.7 19.3 19.2 19 19.6
Wt-z-score −0.74 −1.15 −1.27 −0.99 −1.72
Ht z-score −1.25 −1.59 −1.68 −1.75 −1.35
median cGFR 108.7 99.7 81.7 72.5 84.3
median cGFR 120.9 64 70.9 77.1 83.1
Lung function (LF) stabilised after LT up to 48(A)/24(C) mths, then deteriorated as per
non-LT CF patients. Admissions for chest sepsis reduced in both groups. Patients (A)
with FEV1 40−50% predicted had similar outcome to those with FEV1> 50%. Late
deaths in each group were from respiratory complications. LT did not improve
nutritional status, and pre-OLT BMI did not alter 1 or 5 yr survival. cGFR trends
were comparable to non-CF LT patients.
Conclusion: LT is effective palliative treatment for CFLD, stabilises respiratory disease
but does not improve nutrition.
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cystic ﬁbrosis related diabetes (CFRD) and impaired glucose
tolerance (IGT) in CF centres in the UK
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Increasing life expectancy has resulted in more people with CF developing ab-
normalities of glucose metabolism. The CF Trust published recommendations for
screening and management of CFRD in 2004.
Methods: In 2008 questionnaires were sent to 50 adult (A) and paediatric (P)
CF centres. Data regarding current screening and management practices were
determined and compared to the guidelines.
Results: 40 (80%) questionnaires were returned (20A, 20P). In P oral glucose
tolerance tests (OGTT) were commenced at 10, 12 and 13 yrs in 11, 5 and 1
centres respectively. The majority of centres performed annual OGTT (15A, 16P).
To screen for CFRD 2A centres used HbA1c, 1A and 2P blood glucose monitoring
and 2P used high random glucose as a trigger to initiate an OGTT. Patients identiﬁed
as having IGT were monitored in a variety of ways e.g. repeat OGTT in 6 months,
blood glucose proﬁle/continuous glucose monitoring, assessment of symptoms and
clinical status. 5A and 5P centres would consider treatment with insulin for IGT.
Following a diabetic OGTT a period of home blood glucose monitoring was initiated
at 14A and 4P centres and treatment commenced dependent on the results. P centres
were more likely to refer to the Diabetic Team for management decisions and more
likely to commence insulin therapy without blood glucose monitoring. 16A and
6P centres had joint Diabetic/CF Clinic facilities. Details of dietary and medical
management will be reported.
Conclusion: Despite publication of CFRD guidelines four years prior to the survey
there remains wide variation in practice in UK CF Centres. In light of more recent
evidence and availability of technology guidelines should be reviewed.
